2-pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2571-2586

  DeGoey, David A ^a   Grampovnik, David J ^a   Flentge, Charles A ^a   Flosi, William J ^a   Chen, H J ^a   Yeung, Clinton M ^a   Randolph, John T ^a   Klein, Larry L ^a   Dekhtyar, Tatyana ^a   Colletti, Lynn ^a   Marsh, Kennan C ^a   Stoll, Vincent ^a   Mamo, Mulugeta ^a   Morfitt, David C ^a   Nguyen, Bach ^a   Schmidt, James M ^a   Swanson, Sue J ^a   Mo, Hongmei ^a   Kati, Warren M ^a   Molla, Akhteruzzaman ^a   Kempf, Dale J ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 790742; A 792611; AMPRENAVIR; ATAZANAVIR; BILIRUBIN; INDINAVIR; LOPINAVIR; METHYL 1 [4 HYDROXY 5 [2 [3 [[6 (2 HYDROXYPROPAN 2 YL)PYRIDIN 2 YL]METHYL] 2 OXOIMIDAZOLIDIN 1 YL] 3,3 DIMETHYLBUTANAMIDO] 6 PHENYL 1 [4 (PYRIDIN 2 YL)PHENYL]HEXAN 2 YLAMINO] 3,3 DIMETHYL 1 OXOBUTAN 2 YL CARBAMATE; METHYL [5 [2 (3 BENZYL 2 OXOIMIDAZOLIDIN 1 YL) 3,3 DIMETHYLBUTANAMIDO) 4 HYDROXY 6 PHENYL 1 (4 (PYRIDIN 2 YL)PHENYL]HEXAN 2 YLAMINO] 3,3 DIMETHYL 1 OXOBUTAN 2 YL CARBAMATE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; LIVER MICROSOME; MALE; NONHUMAN; RAT; SIDE EFFECT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN; WILD TYPE; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CARBAMATES; CELL MEMBRANE PERMEABILITY; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; DOGS; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERBILIRUBINEMIA; HYPERLIPIDEMIAS; MICROSOMES, LIVER; MODELS, MOLECULAR; MUTATION; PUTRESCINE; PYRIDINES; RATS; RATS, GUNN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65249123657     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900044w     Document Type: Article

References (34)

1. (a) Kempf, D. J.; Marsh, K. C; Kumar, G.; Rodrigues, A. D.; Denissen, J. F.; McDonald, E.; Kukulka, M. J.; Hsu, A.; Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Plattner, J. J.; Norbeck, D. W.; Leonard, J. M. Pharmacokinetic enhancement of inhibitors of human immunodeficiency virus protease by coadministration of ritonavir. Antimicrob Agents Chemother. 1997, 41 , 654-660.
2. (b) King, J. R.; Wynn, H.; Brundage, R.; Acosta, E. P. Pharmacokinetic enhancement of protease inhibitor therapy. Clin. Pharmacokinet. 2004, 43 , 291-310.
3. (c) Randolph, J. T.; DeGoey, D. A. Peptidomimetic inhibitors of HIV protease. Curr. Top. Med. Chem. 2004, 4 , 1079-1095.
4. Murphy, R. L.; daSilva, B. A.; Hicks, C. B.; Eron, J. J.; Gulick, R. M.; Thompson, M. A.; McMillan, F.; King, M. S.; Hanna, G. J.; Brun, S. C. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin. Trials 2008, 9 , 1-10.
5. Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; Skulnick, H. I.; Dolack, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M.; Lynn, J. C; Chong, K.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S. Tipranavir (PNU-140690) : a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5, 6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 1998, 41 , 3467-3476.
6. Ghosh, A. K.; Dawson, Z. L.; Mitsuya, H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg. Med. Chem. 2007, 15 , 7576-7580.
7. Kempf, D. J.; Waring, J. F.; Morfitt, D. C; Werner, P.; Ebert, B.; Mitten, M.; Nguyen, B.; Randolph, J. T.; DeGoey, D. A.; Klein, L. L.; Marsh, K. Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 2006, 50 , 762-764.
8. Sherer, R. HIV, HAART, and hyperlipidemia: balancing of effects. J. Acquired Immune Defic. Syndr. 2003, 34 , S123-S129.
9. Nolan, D.; Reiss, P.; Mallal, S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin. Drug Saf. 2005, 4 , 201-218.
10. (a) Lum, P. Y.; He, Y. D.; Slatter, J. G.; Waring, J. F.; Zelinsky, N.; Cavet, G.; Dai, X.; Fong, O.; Gum, R.; Jin, L.; Adamson, G. E.; Roberts, C. J.; Olsen, D. B.; Hazuda, D. J.; Ulrich, R. G. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 2007, 90 , 464-473.
11. (b) Waring, J. F.; Ciurlionis, R.; Marsh, K.; Klein, L. L.; DeGoey, D. A.; Randolph, J. T.; Spear, B.; Kempf, D. J. Identification of Proteasome Gene Regulation in a Rat Model for HIV Protease Inhibitor-Induced Hyperlipidemia Using Mcroarray Analysis. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005; Abstract 839.
12. (c) Parker, R. A.; Flint, O. P.; Mulvey, R.; Elosua, C; Wang, F.; Fenderson, W.; Wang, S.; Yang, W.-P.; Noor, M. A. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol. Pharmacol. 2005, 67 , 1909-1919.
13. (d) Waring, J. F.; Ciurlionis, R.; Marsh, K.; Klein, L. L.; DeGoey, D. A.; Randolph, J. T.; Spear, B.; Kempf, D. J. Identification of Proteasome Gene Regulation in a Rat Model for HIV Protease Inhibitor-Induced Hyperlipidemia Using Microarray Analysis. Unpublished results.
14. (a) Flosi, W. J.; DeGoey, D. A.; Grampovnik, D. J.; Chen, H. J.; Klein, L. L.; Dekhtyar, T.; Masse, S.; Marsh, K. C; Mo, H. M.; Kempf, D. J. Discovery of imidazolidine-2, 4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV. Bioorg. Med. Chem. 2006, 14 , 6695-6712.
15. (b) Randolph, J. T.; Huang, P. P.; Flosi, W. J.; DeGoey, D. A.; Klein, L. L.; Yeung, C. M.; Flentge, C.; Sun, M.; Zhao, C.; Dekhtyar, T.; Mo, H; Colletti, L.; Kati, W.; Marsh, K. C.; Molla, A.; Kempf, D. J. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximi-noarylsulfonyl HIV-1 protease inhibitors. Bioorg. Med. Chem. 2006, 14 , 4035-4046.
16. (c) Yeung, C. M.; Klein, L. L.; Flentge, C. A.; Randolph, J. T.; Zhao, C.; Sun, M.; Dekhtyar, T.; Stoll, V.; Kempf, D. J. Oximinoarylsulfonamides as potent HIV protease inhibitors. Bioorg. Med. Chem. Lett. 2005, 15 , 2275-2278.
17. Process improvement of our original synthetic route reported here for the synthesis of core A compounds has been published: Engstrom, K; Henry, R.; Hollis, S.; Kotecki, B.; Marsden, I.; Pu, Y.; Wagaw, S.; Wang, W. An efficient, stereoselective synthesis of the hydroxy-ethylene dipeptide isostere core for the HIV protease inhibitor A-792611. J. Org. Chem. 2006, 71 , 5369-5372.
18. Haight, A. R.; Stuk, T. L.; Allen, M. S.; Bhagavatula, L.; Fitzgerald, M.; Hannick, S. M.; Kerdesky, F. A.; Menzia, J. A.; Parekh, S. I.; Robbins, T. A.; Scarpetti, D.; Tien, J. Reduction of an enaminone: synthesis of the diamino alcohol core of ritonavir. Org. Process Res. Dev. 1999, 3 , 94-100.
19. (a) Zucker, D. S.; Qin, X.; Rouster, S. D.; Yu, F.; Green, R. M.; Keshavan, P.; Feinberg, J.; Sherman, K. E. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 , 12671-12676.
20. (b) Zhang, D.; Chando, T. J.; Everett, D. W.; Patten, C. J.; Dehal, S. S.; Humphreys, W. G. In vitro inhibition of UPD glucuronyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronida-tion. Drug Metab. Dispos. 2005, 33 , 1729-1739.
21. Randolph, J. T.; Huang, P. C.; Flentge, C; DeGoey, D. A.; Flosi, W.; Grampovnik, D.; Yeung, C; Chen, H. J.; Klein, L. L.; Dekhtyar, T.; Mo, H.; Colletti, L.; Kati, W.; Schmidt, J. M.; Turner, T., Marsh, K. C; Molla, A.; Kempf, D. J. A-681799, a Novel HIV Protease Inhibitor. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Oct. 30 through Nov. 2, 2004; Abstract F-485.
22. Kempf, D. J.; Sham, H. L.; Marsh, K. C; Flentge, C. A.; Betebenner, D.; Green, B. E.; McDonald, E.; Vasavanonda, S.; Saldivar, A.; Wideburg, N. E.; Kati, W. M.; Ruiz, L.; Zhao, C; Fino, L.; Patterson, J.; Molla, A.; Plattner, J. J.; Norbeck, D. W. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 1998, 41 , 602-617.
23. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors towards wild-type and mutant human immunodeficiency virus. Viroloey 1998, 250 , 255-262.
24. Carrillo, A.; Stewart, K. D.; Sham, H. L.; Norbeck, D. W.; Kohlbrenner, W. E.; Leonard, J. M.; Kempf, D. J.; Molla, A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol 1998, 72 , 7532-7541.
25. Martinez-Cajas, J. L.; Wainberg, M. A. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 2007, 76 , 203-221.
26. (a) Hosur, M. V.; Bhat, T. N.; Kempf, D. J.; Baldwin, E. T.; Liu, B.; Gulnik, S.; Wideburg, N.; Norbeck, D. W.; Appalt, K.; Erickson, J. W. Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 1994, 116 , 847-855.
27. (b) Stoll, V.; Qin, W.; Stewart, K. D.; Jakob, C; Park, C.; Walter, K.; Simmer, R. L.; Helfrich, R.; Bussiere, D.; Kao, J.; Kempf, D.; Sham, H. L.; Norbeck, D. W. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem. 2002, 10 , 2803-2806.
28. Shafran, S. D.; Mashinter, L. D.; Roberts, S. E. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005, 6 , 421-425.
29. Dekhtyar, T.; Ng, T. I.; Lu, L.; Masse, S.; DeGoey, D. A.; Flosi, W. J.; Grampovnik, D. J.; Klein, L. L.; Kempf, D. J.; Molla, A. Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742. Antimicrob. Agents Chemother. 2008, 52 , 1337- 1344.
30. Hagen, S. E.; Domagala, J.; Gajda, C.; Lovdahl, M.; Tait, B. D.; Wise, E.; Holler, T.; Hupe, D.; Nouhan, C.; Urumov, A.; Zeikus, G.; Zeikus, E.; Lunney, E. A.; Pavlovsky, A.; Gracheck, J. S.; Saunders, J.; VanderRoest, S.; Brodfuehrer, J. 4-Hydroxy-5, 6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J. Med. Chem. 2001, 44 , 2319-2332.
31. Jew, S.; Park, B.; Lim, D.; Kim, M. G.; Chung, I. K.; Kim, J. H.; Hong, J.; Kim, J.; Park, H.; Lee, J.; Park, H. Synthesis of 6-formyl-pyridine-2- carboxylate derivatives and their telomerase inhibitory activities. Bioorg. Med. Chem. Lett. 2003, 13 , 609-612.
32. DeGoey, D. A.; Flentge, C. A.; Flosi, W. J.; Grampovnik, D. J.; Kempf, D. J.; Klein, L. L.; Yeung, M. C.; Randolph, J. T.; Wang, X. C.; Yu, S. HIV protease inhibiting compounds. Patent WO2005058841, 2005.
33. Brunger, A T.; Adams, P. D.; Clore, G M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Ralf, W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G L. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54 , 905.
34. Badger, J.; Berard, D.; Kumar, R. A.; Szalma, S.; Yip, P.; Griesinger, C; Junker, J. CNX Software Manual ; Molecular Simulations, Inc., 1999; www.accelrys.com.